Headquarters: Wilmington, NC, United States
CEO: Mr. David S. Simmons
USD as of Dec. 1, 2021
|Company||Market Cap (USD)|
|MERCK Kommanditgesellschaft auf Aktien||$87.64 B|
|Zoetis Inc.||$68.38 B|
|Takeda Pharmaceutical Company Limited||$46.57 B|
|Eisai Co. Ltd||$17.23 B|
|Shionogi & Co. Ltd||$14.38 B|
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina. As of December 8, 2021, PPD, Inc. operates as a subsidiary of Thermo Fisher Scientific Inc.
Contract clinical research for pharmaceutical, biotechnology, medical device, academic and government organizations; services include drug development, laboratory and lifecycle management.
See Senior Leadership Team page of the P P D Website
Revenue: $4.7 Billion (2020)